What is HC Wainwright’s Estimate for AKRO FY2028 Earnings?

Akero Therapeutics, Inc. (NASDAQ:AKRO) – Equities research analysts at HC Wainwright raised their FY2028 earnings per share estimates for Akero Therapeutics in a research report issued on Monday, November 11th. HC Wainwright analyst E. Arce now anticipates that the company will earn $1.66 per share for the year, up from their prior forecast of $1.47. HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Akero Therapeutics’ current full-year earnings is ($3.82) per share.

Akero Therapeutics (NASDAQ:AKRO) last announced its quarterly earnings results on Friday, November 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.15).

Akero Therapeutics Stock Down 3.9 %

Akero Therapeutics stock opened at $29.76 on Wednesday. The stock has a market cap of $2.08 billion, a PE ratio of -8.26 and a beta of -0.26. The company has a debt-to-equity ratio of 0.05, a quick ratio of 24.89 and a current ratio of 17.25. Akero Therapeutics has a one year low of $13.86 and a one year high of $37.00. The stock has a fifty day moving average of $29.36 and a 200 day moving average of $25.50.

Insider Activity at Akero Therapeutics

In related news, CEO Andrew Cheng sold 108,366 shares of the company’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $31.73, for a total transaction of $3,438,453.18. Following the completion of the sale, the chief executive officer now owns 605,417 shares in the company, valued at approximately $19,209,881.41. This represents a 15.18 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Catriona Yale sold 15,485 shares of the company’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $32.62, for a total value of $505,120.70. Following the sale, the insider now owns 74,158 shares of the company’s stock, valued at approximately $2,419,033.96. This trade represents a 17.27 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 428,397 shares of company stock worth $12,997,971. 7.94% of the stock is owned by insiders.

Institutional Trading of Akero Therapeutics

Several institutional investors have recently made changes to their positions in AKRO. Janus Henderson Group PLC grew its position in shares of Akero Therapeutics by 42.2% during the first quarter. Janus Henderson Group PLC now owns 6,121,970 shares of the company’s stock worth $154,589,000 after purchasing an additional 1,815,569 shares in the last quarter. Redmile Group LLC boosted its stake in Akero Therapeutics by 67.5% during the first quarter. Redmile Group LLC now owns 1,858,702 shares of the company’s stock valued at $46,951,000 after buying an additional 749,226 shares during the last quarter. Vanguard Group Inc. boosted its stake in Akero Therapeutics by 19.0% during the first quarter. Vanguard Group Inc. now owns 3,669,923 shares of the company’s stock valued at $92,702,000 after buying an additional 584,875 shares during the last quarter. Long Focus Capital Management LLC boosted its stake in Akero Therapeutics by 119.0% during the second quarter. Long Focus Capital Management LLC now owns 719,604 shares of the company’s stock valued at $16,882,000 after buying an additional 391,000 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in Akero Therapeutics by 10.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,060,479 shares of the company’s stock valued at $102,569,000 after buying an additional 384,555 shares during the last quarter.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.